Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study.
Journal
CMAJ open
ISSN: 2291-0026
Titre abrégé: CMAJ Open
Pays: Canada
ID NLM: 101620603
Informations de publication
Date de publication:
Historique:
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
19
3
2020
Statut:
epublish
Résumé
Previous costing and resource estimates for cancer have not been complete owing to lack of comprehensive data on cancer-related medication and radiation treatment. Our objective was to calculate the mean overall costs per patient of cancer-related medications and radiation, as well as by disease subtype and stage, in the first year after diagnosis for the 4 most prevalent cancers in Ontario. We conducted a retrospective cohort study using provincial health administrative databases to identify population health system resources and costs for all patients diagnosed with breast, colorectal, lung or prostate cancer between Jan. 1, 2010, and Dec. 31, 2015 in Ontario. The primary outcome measure was the overall average cost per patient in the 365 days after diagnosis for cancer-related medications and radiation treatment, calculated with the use of 2 novel costing algorithms. We determined the cost by disease, disease subtype and stage as secondary outcomes. There were 168 316 Ontarians diagnosed with cancer during the study period, 50 141 with breast cancer, 38 108 with colorectal cancer, 34 809 with lung cancer and 45 258 with prostate cancer. The mean per-patient cost for cancer-related medications was $8167 (95% confidence interval [CI] $8023-$8311), $6568 (95% CI $6446-$6691), $2900 (95% CI $2816-$2984) and $1211 (95% CI $1175-$1247) for breast, colorectal, lung and prostate cancer, respectively. The corresponding mean radiation treatment costs were $18 529 (95% CI $18 415-$18 643), $15 177 (95% CI $14 899-$15 456), $10 818 (95% CI $10 669-$10 966) and $16 887 (95% CI $16 648-$17 125). In general, stage III and IV cancers were the most expensive stages for both medications and radiation across all 4 disease sites. Our work updates previous costing estimates to help understand costs and resources critical to health care system planning in a single-payer system. More refined costing estimates are useful as inputs to allow for more robust health economic modelling and health care system planning.
Sections du résumé
BACKGROUND
Previous costing and resource estimates for cancer have not been complete owing to lack of comprehensive data on cancer-related medication and radiation treatment. Our objective was to calculate the mean overall costs per patient of cancer-related medications and radiation, as well as by disease subtype and stage, in the first year after diagnosis for the 4 most prevalent cancers in Ontario.
METHODS
We conducted a retrospective cohort study using provincial health administrative databases to identify population health system resources and costs for all patients diagnosed with breast, colorectal, lung or prostate cancer between Jan. 1, 2010, and Dec. 31, 2015 in Ontario. The primary outcome measure was the overall average cost per patient in the 365 days after diagnosis for cancer-related medications and radiation treatment, calculated with the use of 2 novel costing algorithms. We determined the cost by disease, disease subtype and stage as secondary outcomes.
RESULTS
There were 168 316 Ontarians diagnosed with cancer during the study period, 50 141 with breast cancer, 38 108 with colorectal cancer, 34 809 with lung cancer and 45 258 with prostate cancer. The mean per-patient cost for cancer-related medications was $8167 (95% confidence interval [CI] $8023-$8311), $6568 (95% CI $6446-$6691), $2900 (95% CI $2816-$2984) and $1211 (95% CI $1175-$1247) for breast, colorectal, lung and prostate cancer, respectively. The corresponding mean radiation treatment costs were $18 529 (95% CI $18 415-$18 643), $15 177 (95% CI $14 899-$15 456), $10 818 (95% CI $10 669-$10 966) and $16 887 (95% CI $16 648-$17 125). In general, stage III and IV cancers were the most expensive stages for both medications and radiation across all 4 disease sites.
INTERPRETATION
Our work updates previous costing estimates to help understand costs and resources critical to health care system planning in a single-payer system. More refined costing estimates are useful as inputs to allow for more robust health economic modelling and health care system planning.
Identifiants
pubmed: 32184283
pii: 8/1/E191
doi: 10.9778/cmajo.20190114
pmc: PMC7082106
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
E191-E198Informations de copyright
Copyright 2020, Joule Inc. or its licensors.
Déclaration de conflit d'intérêts
Competing interests: Natalie Coburn receives salary support from Cancer Care Ontario and the Sherif and MaryLou Hanna Chair in Surgical Oncology at the Sunnybrook Research Institute. No other competing interests were declared.
Références
Curr Oncol. 2014 Jun;21(3):e457-65
pubmed: 24940106
Curr Oncol. 2019 Oct;26(5):e682-e692
pubmed: 31708661
Crit Rev Oncol Hematol. 1999 Nov;32(2):87-93
pubmed: 10612008
CMAJ Open. 2013 Jan 16;1(1):E1-8
pubmed: 25077097
Expert Rev Pharmacoecon Outcomes Res. 2005 Apr;5(2):137-40
pubmed: 19807569
BMC Cancer. 2016 Oct 18;16(1):809
pubmed: 27756310
Neuro Oncol. 2012 May;14(5):631-40
pubmed: 22505658
Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):556-63
pubmed: 25680599
J Clin Oncol. 2018 Jan 20;36(3):238-243
pubmed: 29193984
J Oncol Pract. 2017 Apr;13(4):e283-e290
pubmed: 28291382
Clin Oncol (R Coll Radiol). 2017 Mar;29(3):e57-e63
pubmed: 27956335
Curr Oncol. 2016 Aug;23(4):e392-408
pubmed: 27536189
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):773-83
pubmed: 24726392
PLoS One. 2018 Nov 26;13(11):e0207993
pubmed: 30475890
BJU Int. 2010 Feb;105(3):338-46
pubmed: 19594734
J Oncol Pract. 2009 Jul;5(4):214-5
pubmed: 20856640
Am Health Drug Benefits. 2016 Feb;9(1):23-32
pubmed: 27066193
Br J Cancer. 2016 May 24;114(11):1286-92
pubmed: 27070711
CMAJ. 2016 Feb 16;188(3):182-188
pubmed: 26755672
BMC Health Serv Res. 2017 Aug 1;17(1):511
pubmed: 28764776
J Intellect Disabil Res. 2019 Feb;63(2):124-137
pubmed: 30381849
BMC Health Serv Res. 2014 Oct 31;14:532
pubmed: 25359294
PLoS One. 2016 Mar 03;11(3):e0149179
pubmed: 26937955